Danya Muilwijk

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

The SMART-Youth study: protocol for a longitudinal prospective cohort study to identify disease-associated and lifestyle-associated cardiovascular risk factors for preclinical atherosclerosis in children with a chronic condition.

The SMART-Youth study: protocol for a longitudinal prospective cohort study to identify disease-associated and lifestyle-associated cardiovascular risk factors for preclinical atherosclerosis in children with a chronic condition.

Journal: BMJ open

Published: August 13, 2026

Mental Health Changes in Adolescents and Adults With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Insights From the Longitudinal Resilience Impacted by Positive Stressful Events (RISE) Study.

Mental Health Changes in Adolescents and Adults With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Insights From the Longitudinal Resilience Impacted by Positive Stressful Events (RISE) Study.

Journal: CHEST pulmonary

Published: February 07, 2025

Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls.

Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: May 10, 2024

Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study.

Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 12, 2024

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes.

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes.

Journal: International journal of molecular sciences

Published: August 18, 2023

Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis.

Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis.

Journal: EClinicalMedicine

Published: March 20, 2023

High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing.

High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing.

Journal: ERJ open research

Published: September 28, 2022

Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19.

Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19.

Journal: Frontiers in immunology

Published: September 16, 2022

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis.

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis.

Journal: ERJ open research

Published: April 28, 2022

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Journal: Journal of personalized medicine

Published: November 23, 2021

A new era for people with cystic fibrosis.

A new era for people with cystic fibrosis.

Journal: European journal of pediatrics

Published: April 21, 2021

Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.

Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.

Journal: The European respiratory journal

Published: February 17, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026